In this post hoc analysis of the SPARTAN trial, there was no significant difference in age-related efficacy rates for apalutamide among patients subdivided into the following three age groups: <65, 65 to <75, and 75 or older. There was, however, significantly more Grade 3/4 toxicity among patients in the oldest subgroup (75+).   What I found to be of greater interest, however, was this comment from the author regarding the comparison between enzalutamide and apalutamide: “Apalutamide has been compared with enzalutamide and no significant differences have been observed, although apalutamide has fewer reports of hypertension compared with enzalutamide.”

For the full summary of this ASCO presentation, click here:  https://tinyurl.com/yykm2nlg